NCT07562438
Phase 2 Clinical Trial of 177Lu-P17-088 for mAPMR Prostate Cancer
StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
At risk: Primary endpoint(s) modified.
See at-risk trials from First Affiliated Hospital of Fujian Medical University
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary endpoint(s) modified Show 8 more changesShow less
- Eligibility criteria expanded, about 46 words
- Enrollment closed, study ongoing
- Final enrollment: 25 participants (planned 20)
- Primary completion moved earlier from Dec 31, 2027 to Jun 30, 2027
- Study completion moved earlier from Dec 31, 2028 to Dec 31, 2027
- Site details revised
- Study description expanded, about 5 words
- Study title shortened, about 3 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Prostate-specific antigen 50 (PSA50) response
Timeframe: From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)
Number of participants with Treatment Emergent Adverse Events
Timeframe: From enrollment till 30 days safety follow-up, assessed up to 50 months (estimated final OS analysis)
Dosimetry Data of Tumor and Organs
Timeframe: After administration of 177Lu-P17-088, serial SPECT/CT scans are acquired at Day 0, Day 1, Day 2, Day 3, Day5, and absorbed dose is calculated based on these images.
Secondary (2)
Progression Free Survival (PFS)
Overall Survival (OS)
Arms and interventions
177Lu-P17-088Experimental
Participant will receive 3.7 GBq (+/- 10%) 177Lu-P17-088, once every 6-8 weeks for a planned 4 cycles
Drugs: 177Lu-P17-088
Sites
1 site in 1 country
- Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical UniversityFuzhou, Fujian, China